

**Registered Number 06990371**

**IZON SCIENCE LIMITED**

**Abbreviated Accounts**

**31 March 2013**

## Abbreviated Balance Sheet as at 31 March 2013

	<i>Notes</i>	<i>2013</i>	<i>2012</i>
		£	£
<b>Current assets</b>			
Debtors		424,740	33,410
Cash at bank and in hand		39,056	7,042
		<u>463,796</u>	<u>40,452</u>
<b>Creditors: amounts falling due within one year</b>		(552,931)	(268,487)
<b>Net current assets (liabilities)</b>		<u>(89,135)</u>	<u>(228,035)</u>
<b>Total assets less current liabilities</b>		<u>(89,135)</u>	<u>(228,035)</u>
<b>Total net assets (liabilities)</b>		<u>(89,135)</u>	<u>(228,035)</u>
<b>Capital and reserves</b>			
Called up share capital	2	400,000	1
Profit and loss account		(489,135)	(228,036)
<b>Shareholders' funds</b>		<u>(89,135)</u>	<u>(228,035)</u>

- For the year ending 31 March 2013 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 8 October 2013

And signed on their behalf by:

**J A Van der Voorn, Director**

**Notes to the Abbreviated Accounts for the period ended 31 March 2013****1 Accounting Policies****Basis of measurement and preparation of accounts**

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

**Turnover policy**

Turnover comprises revenue recognised by the company in respect of goods and services supplied during the year, exclusive of Value Added Tax and trade discounts.

**Other accounting policies**

Foreign currencies:

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Profit and loss account.

Research and development:

Development costs are capitalised within intangible assets where they can be identified with a specific product or project anticipated to produce future benefits, and are amortised on the straight line basis over the anticipated life of the benefits arising from the completed product or project.

Deferred research and development costs are reviewed annually, and where future benefits are deemed to have ceased or to be in doubt, the balance of any related research and development is written off to the Profit and loss account.

Ultimate parent undertaking and controlling party:

Mr Van der Voorn has ultimate control of Van der Voorn Investments Limited which owns 47% of IZON Science Limited (New Zealand), which owns 100% of IZON Science Limited (UK). The company Izon Science US Limited is a New Zealand company owned 100% by Izon Science Limited (New Zealand).

Mr Van der Voorn, the sole director, has ultimate control of the company.

**2 Called Up Share Capital**

Allotted, called up and fully paid:

	<i>2013</i>	<i>2012</i>
	<i>£</i>	<i>£</i>
400,000 Ordinary shares of £1 each (1 shares for 2012)	400,000	1

One ordinary share of £1 was allotted to IZON Science Limited (New Zealand) on incorporation and 399,999 further ordinary £1 shares were allotted to IZON Science (New Zealand) on 25/01/2013.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.